Immunoinformatics approach for designing a universal multiepitope vaccine against Chandipura Virus

Chandipura vesiculovirus (CHPV) is a fast-emerging virus that causes acute encephalitis with a high death rate. Because of its extensive prevalence in African and Asian countries, this infection has become a global hazard, and there is an urgent need to create an effective and non-allergenic vaccine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Microbial pathogenesis 2022-01, Vol.162, p.105358-105358, Article 105358
Hauptverfasser: Banik, Anik, Sinha, Shiuly, Ahmed, Sheikh Rashel, Chowdhury, Mohammed Mehadi Hassan, Mukta, Shamsunnahar, Ahmed, Nadim, Rani, Nurul Amin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chandipura vesiculovirus (CHPV) is a fast-emerging virus that causes acute encephalitis with a high death rate. Because of its extensive prevalence in African and Asian countries, this infection has become a global hazard, and there is an urgent need to create an effective and non-allergenic vaccine or appropriate treatment to combat it. A vaccine candidate is offered utilizing a computational technique in this study. To build a potential vaccine candidate, viral protein sequences were acquired from the National Center for Biotechnology Information database and evaluated with several bioinformatics techniques to identify B-cell and T-cell epitopes. V1 was shown to be superior in terms of various physicochemical qualities, as well as highly immunogenic and non-allergic. Molecular docking revealed that the CHPV vaccine construct had a greater binding affinity with human Toll-like receptors (TLR-3 and TLR-8) and that it was stable in molecular dynamics simulations. MEC-CHPV was in silico cloned in the pET28a (+) expression vector using codon optimization. The current research identifies potential antigenic epitopes that could be used as vaccine candidates to eradicate the CHPV. This in-silico development of a CHPV vaccine with multiple epitopes could open the path for future rapid laboratory tests. [Display omitted] •Linkers were used to link epitopes, resulting in possible vaccine candidates.•Designed vaccine was non-allergic and highly antigenic.•For cloning and expression, the proposed construct was modified for E. coli (K12).•The vaccine-TLR3 complex was structurally stable to confer strong immune response.
ISSN:0882-4010
1096-1208
DOI:10.1016/j.micpath.2021.105358